| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
|
Eur J Cancer
|
2009
|
77.71
|
|
2
|
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
|
J Clin Oncol
|
2010
|
14.79
|
|
3
|
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells.
|
Nature
|
2003
|
14.35
|
|
4
|
Polycomb silencers control cell fate, development and cancer.
|
Nat Rev Cancer
|
2006
|
11.48
|
|
5
|
Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation.
|
Nature
|
2003
|
11.23
|
|
6
|
Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing.
|
Mol Cell
|
2005
|
6.29
|
|
7
|
Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.
|
J Clin Invest
|
2005
|
5.90
|
|
8
|
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
|
J Clin Oncol
|
2006
|
4.97
|
|
9
|
Self-renewal as a therapeutic target in human colorectal cancer.
|
Nat Med
|
2013
|
4.20
|
|
10
|
Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha.
|
Immunity
|
2004
|
3.84
|
|
11
|
Bmi1, stem cells, and senescence regulation.
|
J Clin Invest
|
2004
|
3.80
|
|
12
|
Unravelling cancer stem cell potential.
|
Nat Rev Cancer
|
2013
|
3.06
|
|
13
|
Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a).
|
Proc Natl Acad Sci U S A
|
2006
|
2.06
|
|
14
|
Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer.
|
J Clin Invest
|
2012
|
2.03
|
|
15
|
BMI1 sustains human glioblastoma multiforme stem cell renewal.
|
J Neurosci
|
2009
|
1.85
|
|
16
|
BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery.
|
J Neurosci
|
2010
|
1.76
|
|
17
|
The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma.
|
Cancer Res
|
2008
|
1.56
|
|
18
|
BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression.
|
Cancer Res
|
2008
|
1.56
|
|
19
|
Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer.
|
J Cancer Res Clin Oncol
|
2009
|
1.41
|
|
20
|
Cancer stem cells: A contentious hypothesis now moving forward.
|
Cancer Lett
|
2013
|
1.40
|
|
21
|
Monoubiquitination of H2AX protein regulates DNA damage response signaling.
|
J Biol Chem
|
2011
|
1.29
|
|
22
|
Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas.
|
Clin Cancer Res
|
2006
|
1.23
|
|
23
|
Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study.
|
J Cancer Res Clin Oncol
|
2008
|
1.21
|
|
24
|
Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death.
|
Oncogene
|
2006
|
1.19
|
|
25
|
A positive feedback loop regulates the expression of polycomb group protein BMI1 via WNT signaling pathway.
|
J Biol Chem
|
2012
|
1.07
|
|
26
|
Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma.
|
PLoS One
|
2011
|
1.00
|
|
27
|
PTEN inhibits BMI1 function independently of its phosphatase activity.
|
Mol Cancer
|
2009
|
0.97
|
|
28
|
Drug-induced QT interval prolongation: mechanisms and clinical management.
|
Ther Adv Drug Saf
|
2012
|
0.94
|
|
29
|
Bmi1 confers resistance to oxidative stress on hematopoietic stem cells.
|
PLoS One
|
2012
|
0.91
|
|
30
|
Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590.
|
Lung Cancer
|
2007
|
0.89
|
|
31
|
Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.
|
Med Res Rev
|
2015
|
0.88
|
|
32
|
BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling.
|
PLoS One
|
2013
|
0.86
|
|
33
|
Bmi1 gene silencing inhibits the proliferation and invasiveness of human hepatocellular carcinoma cells and increases their sensitivity to 5-fluorouracil.
|
Oncol Rep
|
2012
|
0.82
|
|
34
|
Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells.
|
Indian J Exp Biol
|
2011
|
0.82
|
|
35
|
Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy.
|
Cancer Sci
|
2015
|
0.81
|